Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GDC-0927 is a novel,non-steroidal, potent, orally bioavailable, selective estrogen receptor antagonist.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 mg | 5 days | $ 747.00 | |
25 mg | 5 days | $ 1,610.00 | |
50 mg | 5 days | $ 2,570.00 |
Description | GDC-0927 is a novel,non-steroidal, potent, orally bioavailable, selective estrogen receptor antagonist. |
In vivo | GDC-0927, a novel and potent non-steroidal, orally bioavailable selective estrogen receptor (ER) antagonist/degrader (SERD), effectively induces tumor regression in patient-derived xenograft models of estrogen receptor-positive (ER+) breast cancer (BC). |
Synonyms | SRN-927 |
Molecular Weight | 461.52 |
Formula | C28H28FNO4 |
CAS No. | 1642297-01-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 83.33 mg/mL (180.56 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GDC-0927 1642297-01-5 Others SRN 927 GDC 0927 SRN-927 GDC0927 SRN927 inhibitor inhibit